A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.

Author:

Paper Details 
Original Abstract of the Article :
Standard or conventional treatment of chronic myeloid leukemia (CML) had little effect on the course and the duration of the disease. Treatment with human natural and recombinant alpha-interferon (IFN) was shown to induce hematologic responses, together with partial or complete repopulation of the m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/1427426

データ提供:米国国立医学図書館(NLM)

A Comparative Study of Alpha-IFN and Conventional Chemotherapy in Ph+ Chronic Myeloid Leukemia

This research, conducted by the Italian Cooperative Study Group on Chronic Myeloid Leukemia, investigates a crucial aspect of cancer treatment: the effectiveness of alpha-interferon (IFN) compared to conventional chemotherapy in the management of Ph+ chronic myeloid leukemia (CML). The study employed a prospective comparison design, enabling the researchers to carefully analyze the long-term outcomes of both treatment approaches.

Alpha-IFN: A Promising Alternative

The study's findings offer a ray of hope for patients with CML. The results revealed that treatment with alpha-IFN induced hematologic responses, along with a notable partial or complete repopulation of the marrow with Ph-negative cells. This positive outcome suggests that alpha-IFN holds significant promise as an effective treatment for CML, offering a potential alternative to conventional chemotherapy with its associated side effects.

New Horizons in CML Treatment

This research has significant implications for the future of CML treatment. It paves the way for further exploration of alpha-IFN and its potential to transform the management of this complex disease. The findings are like discovering a hidden oasis in the vast desert of cancer research, offering a new source of hope and a renewed focus on personalized treatment strategies.

Dr.Camel's Conclusion

The study's findings underscore the need for a more nuanced approach to CML treatment, taking into account the diverse needs and characteristics of individual patients. It's like a journey through the desert landscape, where each patient's experience is unique. The study highlights the potential benefits of alpha-IFN, offering a promising new avenue for treatment and potentially improving the long-term well-being of CML patients.

Date :
  1. Date Completed 1992-12-11
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

1427426

DOI: Digital Object Identifier

1427426

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.